Stockreport

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) MiNK Therapeut [Read more]